{
  "docId": "019de072-4935-7342-8528-4e6eca3fe5c7",
  "docSlug": "31ea92baba83669e6443d115d329d67b",
  "documentTitle": "AstraZeneca | Investor Presentation Deck | 53 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 53,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Includes a stacked bar chart for Farxiga revenue and a line chart for Lokelma market share.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-4935-7342-8528-4e6eca3fe5c7/22",
  "deckHref": "/decks/019de072-4935-7342-8528-4e6eca3fe5c7",
  "deckJsonHref": "/decks/019de072-4935-7342-8528-4e6eca3fe5c7.json",
  "deckAnchorHref": "/decks/019de072-4935-7342-8528-4e6eca3fe5c7#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.09,
        "x": 0.56,
        "y": 0.76
      },
      "kind": "callout",
      "text": "Now blockbuster status in EM",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6c6ae4d-a462-45aa-baa2-5811fe46f8fe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.32,
        "x": 0.04,
        "y": 0.33
      },
      "kind": "chart",
      "text": "Farxiga revenue by region over time",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d7680875-2d96-41b1-b7fa-c9541210249c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.66,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Lokelma US branded K+ binder TRx share",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bf9dd555-37ab-4956-ac47-196bdb8b25d7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.35,
        "y": 0.42
      },
      "kind": "list",
      "text": "US +29%, Europe +52% and EM +70%, boosted by HFrEF and CKD launches. Volumes growing faster than the SGLT2i market. China NRDL status renewed. #1 innovative anti-diabetic in China and Brazil.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "117e2add-e8fc-452f-af4d-6cd398040bda",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.66,
        "y": 0.68
      },
      "kind": "list",
      "text": "Continued strong growth in US and Japan. Expanding in new markets in Europe. China NRDL listing from January 2022.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "915b44a3-274b-4eb5-ac1a-bbcd8f7992c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.4,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Total Revenue $8.0bn; growth +9%",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef5a3a5c-ce4e-4beb-af6d-4ac4a2ec7dae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.82,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "BioPharmaceuticals: Cardiovascular, Renal and Metabolism",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7a652e45-f034-471d-b54d-36a5a6b639f8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 26,
      "from": 9,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "e1c98b8b-502c-44c3-8a4f-5b036b65dd56",
      "evidence": "The deck presents a golden circle narrative, highlighting why AstraZeneca is positioned for growth, how they will achieve it, and what the results are",
      "position": 0,
      "objective": "Why AstraZeneca is positioned for growth",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}